Increase in IL-6 levels among major depressive disorder patients after a 6-week treatment with duloxetine 60 mg/day: a preliminary observation
Open accessThe DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Immune modifications, including changes in interleukin (IL)-6 levels, have often been observed in major depressive disorder (MDD) during treatment with selective serotonin reuptake inhibitors (SSRIs) or the serotonin norepinephrine reuptake inhibitor (SNRI) venlafaxine. Nevertheless, no equivalent observation for the SNRI duloxetine has been made to date. METHOD: Sixteen patients diagnosed with MDD and an actual major depressive episode according to DSM-IV criteria and 16 healthy controls entered a 6-week trial with duloxetine 60 mg/day. All subjects (n = 32) were assessed using the Hamilton Depression Rating Scale (HAM-D), the Young Mania Rating Scale (YMRS), and were monitored for IL-6 levels both at baseline and at week 6. Blood samples for IL-6 levels were evaluated by ELISA. RESULTS: After 6 weeks of treatment, the mean total scores for HAM-D declined both in the depressed and control groups, while IL-6 modification showed an opposite trend both in depressed (12.38 ± 19.80 to 19.73 ± 18.94 pg/mL) and control subjects (12.25 ± 21.12 to 17.63 ± 20.44 pg/mL), as did YMRS (ns), although none of the subjects switched to (hypo)mania. Of note, IL-6 levels increased significantly only in the responders subgroup (n = 9; P = 0.012). CONCLUSION: The small sample size and weak design of this study limit the validity of our results, which should be regarded as preliminary only. Nonetheless, the trend of increasing IL-6 levels observed in responder patients treated with duloxetine should prompt further controlled, extended studies with larger samples, with the specific aim of better assessing a putative differential role of norepinephrinergic antidepressant stimulation of serotonergic reuptake inhibition in determining modifications in IL-6 levels. Ideally, more accurate replication studies may contribute to further understanding of the complex interaction of mood, antidepressant response, and the immune system.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Comorbidity: a network perspective
Cramer, A. O. J., Waldorp, L. J., van der Maas, H. L. J., & Borsboom, D. (2010) · Behavioral and Brain Sciences · doi:10.1017/s0140525x09991567 · Cited by 1,575 · cited 1×
“Investigations of immune imbalances in the course of major depressive disorder (MDD) have demonstrated higher serum concentration of some cytokines such as IL-6 (a Th2-type cytokine), IL-1, and TNFα (Th1 cytokines), with similar findings shown also in course of anxious states, reflecting a substantial psychopathologic…”
Cytokine Production and Treatment Response in Major Depressive Disorder
Lanquillon, S. (2000) · Neuropsychopharmacology · doi:10.1016/s0893-133x(99)00134-7 · Cited by 735 · cited 1×
“Lanquillon et al found an increase in mean IL-6 levels of responders after antidepressant treatment, while it remained high in nonresponders.(5) Frommberger et al found a decrease in the IL-6 levels of depressed patients after treatment with antidepressants.”
Major Depression and Activation of The Inflammatory Response System
Maes, M. (1999) · Advances in Experimental Medicine and Biology · doi:10.1007/978-0-585-37970-8_2 · Cited by 617
Training and quality assurance with the structured clinical interview for DSM-iV (SCID-I/P)
Ventura, J., Liberman, R. P., Green, M. F., Shaner, A., & Mintz, J. (1998) · Psychiatry Research · doi:10.1016/s0165-1781(98)00038-9 · Cited by 591 · cited 1×
“All diagnoses were made according to the Diagnostic and Statistical Manual for Mental Disorders (Fourth Edition) (DSM-IV) criteria(19) assessed by the Structured Clinical Interview for Axis-I Disorders/Patient edition (SCID-I/P).(20) At baseline, 16 patients were eligible to enter the study (3 did not sign the informe…”
Effects of antidepressants on the production of cytokines
Kenis, G., & Maes, M. (2002) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145702003164 · Cited by 370 · cited 1×
“…in relation to levels of cytokines and their modulation after treatment with tricyclic antidepressants (TCAs), some studies showed that this class of drugs inhibits the IL-1 β , IL-2, TNF-alpha, and INF-γ (Th1-type cytokines) 29,30 and may enhance the production of IL-10 (Th2-type cytokines).”
Frommberger, U. H., Bauer, J., Haselbauer, P., Fräulin, A., Riemann, D., & Berger, M. (1997) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/bf02900219 · Cited by 362 · cited 1×
“Frommberger et al found a decrease in the IL-6 levels of depressed patients after treatment with antidepressants.(28) De Berardis et al,(12) in a systematic review of immunological modulation in the course of antidepressant therapy, including venlafaxine, found that IL-6 levels decreased at low doses (as generally obs…”
Kubera, M., Lin, A.-H., Kenis, G., Bosmans, E., van Bockstaele, D., & Maes, M. (2001) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200104000-00012 · Cited by 343
Elenkov, I. J. (2008) · Neurochemistry International · doi:10.1016/j.neuint.2007.06.037 · Cited by 273 · cited 4×
“Therefore, since catecholamines upregulate IL-6 production, the chronic hyper-noradrenergic state, essentially promoted by NA-ergic stimulation, may drive the increase in systemic IL-6 levels.(2) Interestingly, baseline IL-6 levels in patients in treatment remission after 6 weeks were considerably higher than in those…”
InfluentialA psychoneuroimmunological review on cytokines involved in antidepressant treatment response
Janssen, D. G. A., Caniato, R. N., Verster, J. C., & Baune, B. T. (2010) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.1103 · Cited by 240 · cited 1×
“10 To date, most of the immunological investigations carried out in MDD patients treated with antidepressant drugs focused on IL-6 modifications in the course of serotonergic selective serotonin reuptake inhibitors (SSRIs) treatment, which is still the most frequently prescribed class of…”
Low cortisol, high DHEA, and high levels of stimulated TNF‐α, and IL‐6 in women with PTSD
Gill, J., Vythilingam, M., & Page, G. G. (2008) · Journal of Traumatic Stress · doi:10.1002/jts.20372 · Cited by 240
Antidepressants inhibit interferon-γ-induced microglial production of IL-6 and nitric oxide
Hashioka, S., Klegeris, A., Monji, A., Kato, T., Sawada, M., McGeer, P. L., & Kanba, S. (2007) · Experimental Neurology · doi:10.1016/j.expneurol.2007.03.022 · Cited by 198
Stimulatory effect of antidepressants on the production of IL-6
Kubera, M., Kenis, G., Bosmans, E., Kajta, M., Basta-Kaim, A., Scharpe, S., Budziszewska, B., & Maes, M. (2004) · International Immunopharmacology · doi:10.1016/j.intimp.2003.11.006 · Cited by 126 · cited 5×
“If these results could be confirmed by more rigorous investigations, it may be hypothesized that the balance 5-HT/NA may modulate the levels of IL-6.”
InfluentialClinical evidence for serotonin and norepinephrine reuptake inhibition of duloxetine
Trivedi, M. H., Desaiah, D., Ossanna, M. J., Pritchett, Y. L., Brannan, S. K., & Detke, M. J. (2008) · International Clinical Psychopharmacology · doi:10.1097/yic.0b013e3282f41d7e · Cited by 59 · cited 1×
“Furthermore, duloxetine is supposed to act as a balanced (1:1), pro-serotonergic and pro-norepinephrinergic drug independently on its dosage, 18 thus IL-6 levels upon duloxetine administration would be expected to follow a linear trend even at low doses (eg, 60 mg/day or lower).”
Cited by
Haapakoski, R., Mathieu, J., Ebmeier, K. P., Alenius, H., & Kivimäki, M. (2015) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2015.06.001 · Cited by 1,129
“Frodl T, Carballedo A, Hughes MM, Saleh K, Fagan A, Skokauskas N, McLoughlin DM, Meaney J, O'Keane V, Connor TJ. Reduced expression of glucocorticoid-inducible genes GILZ and SGK-1: high IL-6 levels are associated with reduced hippocampal volumes in major depressive disorder.”
InfluentialOsimo, E. F., Pillinger, T., Rodriguez, I. M., Khandaker, G. M., Pariante, C. M., & Howes, O. D. (2020) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2020.02.010 · Cited by 937
“The final data set included 107 studies(13, 16, 17, 34-139), covering data on 306 immune measures”
Hannestad, J., DellaGioia, N., & Bloch, M. (2011) · Neuropsychopharmacology · doi:10.1038/npp.2011.132 · Cited by 914
Inflammation and clinical response to treatment in depression: A meta-analysis
Strawbridge, R., Arnone, D., Danese, A., Papadopoulos, A., Herane Vives, A., & Cleare, A. J. (2015) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2015.06.007 · Cited by 666
“…were sufficiently researched to be included in primary analyses: interleukin-6 (IL-6) in 12 studies (Basterzi et al., 2005; Carvalho et al., 2012; Fornaro et al., 2011; Frommberger et al., 1997; Kubera et al., 2000; Lanquillon et al., 2000; Maes et al., 1997a; Maes et al., 1995; MarquesDeak et…”
InfluentialLiu, J. J., Wei, Y. B., Strawbridge, R., Bao, Y., Chang, S., Shi, L., Que, J., Gadad, B. S., Trivedi, M. H., Kelsoe, J. R., et al. (2020) · Molecular Psychiatry · doi:10.1038/s41380-019-0474-5 · Cited by 429
Metadata
- Authors
- Fornaro, M., Martino, Battaglia, F., Colicchio, & Perugi
- Venue
- Neuropsychiatric Disease and Treatment
- Publisher
- Informa UK Limited
- Published
- 2011-02
- Volume
- 7
- Pages
- 51
- ISSN
- 1176-6328 (ISSN-L)
- OpenAlex
- W2107552020
- Cited by
- 45
- References
- 13
- FWCI
- 1.07
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.